<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113643</url>
  </required_header>
  <id_info>
    <org_study_id>17-056</org_study_id>
    <nct_id>NCT03113643</nct_id>
  </id_info>
  <brief_title>SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</brief_title>
  <official_title>Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stemline Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN&#xD;
      and high-risk MDS.&#xD;
&#xD;
      The interventions involved in this study are:&#xD;
&#xD;
        -  SL-401&#xD;
&#xD;
        -  Azacitidine&#xD;
&#xD;
        -  Venetoclax&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase I clinical trial, which tests the safety of an investigational&#xD;
      intervention and also tries to define the appropriate dose of the investigational&#xD;
      intervention to use for further studies. &quot;Investigational&quot; means that the intervention is&#xD;
      being studied.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has approved azacitidine and venetoclax as a&#xD;
      treatment option for AML. However, the combination of these two drugs with SL-401 has not&#xD;
      been FDA approved.&#xD;
&#xD;
      The combination of SL-401, azacitidine and venetoclax has not been FDA approved for BPDCN.&#xD;
      However, SL-401 has been FDA approved for BPDCN.&#xD;
&#xD;
      The combination of SL-401 and azacitidine has not been FDA approved for BPDCN.&#xD;
&#xD;
      In this research study, the study drug SL-401 will be combined with the standard dose of&#xD;
      azacitidine (for MDS patients) or azacitidine/venetoclax (for AML and BPDCN patients). The&#xD;
      goal of this research study is to try and determine the safest, highest dose of study drug,&#xD;
      SL-401, in combination with azacitidine or azacitidine/venetoclax that can be given to&#xD;
      patients with AML, BPDCN or high-risk MDS. SL-401 works by stopping or slowing the growth of&#xD;
      cancer stem cells, which are the undeveloped cells which can develop into cancer cells. The&#xD;
      goals of this research study are to look at if this combination works to help treat your&#xD;
      cancer and if there is any lasting effect of this combination. This study will also look at&#xD;
      how the SL-401, in combination with azacitidine or azacitidine/venetoclax, affects certain&#xD;
      proteins in your blood and bone marrow. SL-401 has been given to patients with AML, and MDS&#xD;
      in the past, but this is the first time it will be given in combination with another drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax in this patient population and evaluate the safety of this regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate the complete remission (CR) / CR with incomplete count recovery (CRi) rate within 6 cycles of combination therapy consisting of SL-401 administered with azacitidine or in combination with azacitidine and venetoclax in subjects with AML and high-risk MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate the time to response with SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate the duration of remission with SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>To estimate the 1 and 2-year progression free survival (PFS) with SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate the overall survival (OS) with SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>SL-401+ Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SL-401+ Azacitidine + Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>SL-401+ Azacitidine</arm_group_label>
    <arm_group_label>SL-401+ Azacitidine + Venetoclax</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL-401</intervention_name>
    <description>SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.</description>
    <arm_group_label>SL-401+ Azacitidine</arm_group_label>
    <arm_group_label>SL-401+ Azacitidine + Venetoclax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.</description>
    <arm_group_label>SL-401+ Azacitidine + Venetoclax</arm_group_label>
    <other_name>Venclyxto, Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically confirmed diagnosis of acute myeloid leukemia (AML) [Cohort B] or&#xD;
        myelodysplastic syndrome (MDS) [Cohort A] or BPDCN [Cohort C] per 2016 WHO criteria&#xD;
&#xD;
        CD123 / IL3RA expression on the subject's AML or MDS blasts or BPDCN cells determined&#xD;
        locally within 3 months of first protocol treatment&#xD;
&#xD;
        Age &gt;= 18 years with relapsed or refractory AML (hydroxyurea is not considered a prior&#xD;
        treatment regimen) [Cohort B]&#xD;
&#xD;
        OR&#xD;
&#xD;
        Age &gt;= 18 years with treatment-na√Øve AML who decline intensive induction chemotherapy or&#xD;
        who are unfit due to co-morbidity or other factors (see APPENDIX A for unfitness&#xD;
        definitions) (hydroxyurea is not considered a prior treatment regimen) [Cohort B]&#xD;
&#xD;
        OR&#xD;
&#xD;
        Age &gt;= 18 years with MDS and &gt; 10% myeloblasts in the bone marrow [Cohort A]&#xD;
&#xD;
        OR&#xD;
&#xD;
        Age &gt;= 18 years with relapsed or refractory BPDCN (hydroxyurea is not considered a prior&#xD;
        treatment regimen) [Cohort C]&#xD;
&#xD;
        Adequate organ function as defined by:&#xD;
&#xD;
        Albumin &gt; 3.2 g/dL (in the absence of receipt of intravenous albumin in the previous 72&#xD;
        hours) Serum creatinine &lt; 1.5x ULN Aspartate aminotransferase (AST) and alanine&#xD;
        aminotransferase (ALT) &lt; 2.5x ULN Total bilirubin &lt; 1.5x ULN (if thought to be &gt; 1.5x ULN&#xD;
        due to Gilbert's disease or the patient's AML, must discuss with the PI) Creatine&#xD;
        phosphokinase (CPK) &lt; 2.5x ULN Left ventricular ejection fraction &gt; institutional lower&#xD;
        limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment&#xD;
&#xD;
        [Cohorts B and C] WBC &lt; 20,000 / uL on day of first therapy, cytoreduction may be achieved&#xD;
        using hydroxyurea&#xD;
&#xD;
        Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Able to adhere to study visit schedule and other protocol requirements including follow-up&#xD;
        for survival assessment&#xD;
&#xD;
        Women of child-bearing potential must agree to use adequate contraception for the duration&#xD;
        of study participation and for 2 months after completion of protocol treatment.&#xD;
&#xD;
        Men treated or enrolled on this protocol must also agree to use adequate contraception for&#xD;
        the duration of study participation and 2 months after completion of protocol treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prior treatment with venetoclax [Cohorts B or C], unless it was last taken &gt;2 months before&#xD;
        protocol therapy&#xD;
&#xD;
        Diagnosis of acute promyelocytic leukemia&#xD;
&#xD;
        Received treatment with chemotherapy, radiation, or biologic cancer therapy within 14 days&#xD;
        of first protocol treatment, except for intrathecal chemotherapy. Prior and concurrent&#xD;
        hydroxyurea is permitted.&#xD;
&#xD;
        Hematopoietic stem cell transplantation (HSCT) within 60 days of screening or active graft&#xD;
        versus-host-disease&#xD;
&#xD;
        Active CNS involvement by AML or BPDCN. Screening lumbar puncture (LP) required for&#xD;
        patients with BPDCN. If history of treated CNS involvement, must have had two consecutive&#xD;
        negative LPs since last CNS involvement, which may include the screening LP&#xD;
&#xD;
        Known positive status for HIV infection; known active hepatitis B or hepatitis C infection&#xD;
&#xD;
        Clinically significant cardiopulmonary disease including uncontrolled or NYHA class 3 or 4&#xD;
        congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled&#xD;
        arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment, or&#xD;
        QTc &gt; 480 ms&#xD;
&#xD;
        Patients with known active advanced malignant solid tumors are excluded (except for basal&#xD;
        or squamous skin cancers, or carcinomas in situ). Patients with additional hematologic&#xD;
        malignancies that require treatment are excluded.&#xD;
&#xD;
        Pregnant women are excluded from this study because there is an unknown but potential risk&#xD;
        for adverse events in the developing fetus with SL-401, azacitidine, and venetoclax&#xD;
        (negative urine or serum pregnancy test required within 14 days of Cycle 1, Day 1). Because&#xD;
        nursing infants have unknown potential for adverse events secondary to treatment of the&#xD;
        mother, breastfeeding should be discontinued if the mother is treated with SL-401,&#xD;
        azacitidine, and venetoclax.&#xD;
&#xD;
        Patients with uncontrolled infection shall not be enrolled until infection is treated and&#xD;
        brought under control. Patients with active infection are permitted to enroll provided that&#xD;
        the infection is controlled&#xD;
&#xD;
        [Cohorts B and C] Patients with gastrointestinal (GI) tract disease causing the inability&#xD;
        to take oral medication, malabsorption syndrome, a requirement for intravenous (IV)&#xD;
        alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI&#xD;
        disease (e.g., Crohn's disease, ulcerative colitis)&#xD;
&#xD;
        [Cohorts B and C] Patients on strong CYP3A inducers within 7 days of first dose of study&#xD;
        treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Lane, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Lane, MD, PhD</last_name>
    <phone>617-632-4589</phone>
    <email>andrew_lane@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Stein, MD</last_name>
      <phone>626-359-8111</phone>
      <email>AStein@coh.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Lane, MD, PhD</last_name>
      <phone>617-582-7386</phone>
      <email>andrew_lane@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Lane, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen Pemmaraju, MD</last_name>
      <phone>713-792-4956</phone>
      <email>npemmaraju@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naveen Pemmaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Andrew Lane</investigator_full_name>
    <investigator_title>Andrew Lane, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Blastic Plasmacytoid Dendritic Cell Neoplasm</keyword>
  <keyword>BPDCN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

